MUTATIONAL ANALYSIS OF A TYPE-II TOPOISOMERASE CLEAVAGE SITE - DISTINCT REQUIREMENTS FOR ENZYME AND INHIBITORS

被引:57
作者
FREUDENREICH, CH [1 ]
KREUZER, KN [1 ]
机构
[1] DUKE UNIV,MED CTR,DEPT MICROBIOL & IMMUNOL,DURHAM,NC 27710
关键词
ANTITUMOR AGENT; BACTERIOPHAGE-T4; INHIBITOR; OLIGONUCLEOTIDE; TYPE-II TOPOISOMERASE;
D O I
10.1002/j.1460-2075.1993.tb05857.x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have analyzed the DNA sequence requirements for cleavage of a 30 bp oligonucleotide that contains a strong bacteriophage T4 type II topoisomerase site. A novel method was used to generate substrates with each of the four nucleotides at 10 positions surrounding the cleavage site, and mutant substrates were also prepared for the four internal positions of the staggered cleavage site. The substrates were tested for cleavage in the presence of several inhibitors that induce enzyme-mediated cleavage: four antitumor agents of different classes (an aminoacridine, a substituted anthraquinone, an ellipticine derivative and an epipodophyllotoxin) and one antibacterial quinolone. At eight nucleotide positions flanking the cleavage site, the same preferred bases were found regardless of which inhibitor was present. These preferred bases show dyad symmetry with respect to the cleavage site, indicating that both protomers of the topoisomerase homodimer interact with DNA in an analogous manner. In addition, we found that the preferred bases on the 5' side of each cleaved phosphodiester bond are highly specific to the inhibitor used in the cleavage reaction. These results strongly suggest that the inhibitors interact directly with the DNA bases at the cleavage site, placing the inhibitor binding site precisely at the site of DNA cleavage.
引用
收藏
页码:2085 / 2097
页数:13
相关论文
共 55 条
[1]   DESIGN OF DNA INTERCALATORS TO OVERCOME TOPOISOMERASE II-MEDIATED MULTIDRUG RESISTANCE [J].
BAGULEY, BC ;
HOLDAWAY, KM ;
FRAY, LM .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (05) :398-402
[2]   INSITU LOCALIZATION OF DNA TOPOISOMERASE-II, A MAJOR POLYPEPTIDE COMPONENT OF THE DROSOPHILA NUCLEAR MATRIX-FRACTION [J].
BERRIOS, M ;
OSHEROFF, N ;
FISHER, PA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (12) :4142-4146
[3]   TOPOISOMERASE FROM ESCHERICHIA-COLI RELATED TO DNA GYRASE [J].
BROWN, PO ;
PEEBLES, CL ;
COZZARELLI, NR .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (12) :6110-6114
[4]   LOCAL SEQUENCE REQUIREMENTS FOR DNA CLEAVAGE BY MAMMALIAN TOPOISOMERASE-II IN THE PRESENCE OF DOXORUBICIN [J].
CAPRANICO, G ;
KOHN, KW ;
POMMIER, Y .
NUCLEIC ACIDS RESEARCH, 1990, 18 (22) :6611-6619
[5]   SEQUENCE-SELECTIVE TOPOISOMERASE-II INHIBITION BY ANTHRACYCLINE DERIVATIVES IN SV40 DNA - RELATIONSHIP WITH DNA-BINDING AFFINITY AND CYTOTOXICITY [J].
CAPRANICO, G ;
ZUNINO, F ;
KOHN, KW ;
POMMIER, Y .
BIOCHEMISTRY, 1990, 29 (02) :562-569
[6]   A THEORETICAL INVESTIGATION ON THE SEQUENCE SELECTIVE BINDING OF MITOXANTRONE TO DOUBLE-STRANDED TETRANUCLEOTIDES [J].
CHEN, KX ;
GRESH, N ;
PULLMAN, B .
NUCLEIC ACIDS RESEARCH, 1986, 14 (09) :3799-3812
[7]   NOVEL BLUNT-END ADDITION-REACTIONS CATALYZED BY DNA-POLYMERASE-I OF ESCHERICHIA-COLI [J].
CLARK, JM ;
JOYCE, CM ;
BEARDSLEY, GP .
JOURNAL OF MOLECULAR BIOLOGY, 1987, 198 (01) :123-127
[9]   TOPOISOMERASE-TARGETING ANTITUMOR DRUGS [J].
DARPA, P ;
LIU, LF .
BIOCHIMICA ET BIOPHYSICA ACTA, 1989, 989 (02) :163-177
[10]   INHIBITORS OF DNA TOPOISOMERASE-II PREVENT CHROMATID SEPARATION IN MAMMALIAN-CELLS BUT DO NOT PREVENT EXIT FROM MITOSIS [J].
DOWNES, CS ;
MULLINGER, AM ;
JOHNSON, RT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (20) :8895-8899